原发性胆汁性胆管炎的遗传学研究现状

李奕康; 马雄; 唐茹琦

doi:10.3969/j.issn.1001-5256.2017.11.011

原发性胆汁性胆管炎的遗传学研究现状

DOI: 10.3969/j.issn.1001-5256.2017.11.011

上海交通大学医学院附属仁济医院消化内科上海市消化病研究所

详细信息

中图分类号: R575.22
计量
- 文章访问数: 2226
- HTML全文浏览量: 16
- PDF下载量: 485
- 被引次数: 0
出版历程
- 收稿日期: 2017-08-24
- 出版日期: 2017-11-20

Advances in genetic research on primary biliary cholangitis

Department of Gastroenterology, Renji Hospital, Renji Hospital, Shanghai Jiao Tong University School of Medicine & Shanghai Institute of Digestive Diseases

摘要

摘要: 原发性胆汁性胆管炎(PBC)是一种具有明显遗传易感性的自身免疫性肝病。近年来开展的全基因组关联分析和基因芯片等遗传学研究,在揭示PBC的发病机制中发挥着重要的作用。PBC的易感基因主要分为人类白细胞抗原基因和非人类白细胞抗原基因两大类,其易感位点大多与免疫调节相关,表明免疫调节通路紊乱可能在PBC的发病中起关键作用。此外,这些候选基因的加权基因风险评分在一定程度上可能预测PBC的发病风险。如今,约有1/3的PBC患者对现有的PBC标准治疗药物熊去氧胆酸反应不佳。因此,易感基因对应的靶向药物有望成为有效的替代疗法。
- 胆管炎,胆汁性 /
- 胆汁淤积 /
- 疾病遗传易感性
Abstract: Primary biliary cholangitis (PBC) is an autoimmune liver disease with strong genetic susceptibility.The genome-wide association studies and immunochip studies conducted in recent years help to reveal the pathogenesis of PBC.The susceptibility genes of PBC are classified into human leukocyte antigen gene and non-human leukocyte antigen gene, and most of the susceptibility loci are associated with immune regulation, suggesting that disorders of the immune regulatory pathways may play an important role in the pathogenesis of PBC.In addition, the weighted genetic risk score of these candidate genes may predict the risk of PBC.At present, about one third of PBC patients have suboptimal response to ursodeoxycholic acid;therefore, targeted drugs for susceptibility genes may become an effective substitutive therapy.
- cholangitis, biliary /
- cholestasis /
- genetic predisposition to disease

HTML全文

参考文献(58)

[1]PUROHIT T, CAPPELL MS, et al.Primary biliary cirrhosis:pathophysiology, clinical presentation and therapy[J].World JHepatol, 2015, 7 (7) :926-941.

[2]HIRSCHFIELD GM, SIMINOVITCH KA, et al.Genetic in PBC:what do the“risk genes”teach us?[J].Clinic Rev Allerg Immunol, 2015, 48 (2-3) :176-181.

[3]WONG GL, HUI AY, WONG VW, et al.A retrospective study on clinical features and prognostic factors of biopsy-proven primary biliary cirrhosis in Chinese patients[J].Am J Gastroenterol, 2005, 100 (10) :2205-2211.

[4]FLORES A, MAYO MJ.Primary biliary cirrhosis in 2014[J].Curr Opin Gastroenterol, 2014, 30 (3) :245-252.

[5]TRYNKA G, HUNT KA, BOCKETT NA, et al.Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease[J].Nat Genet, 2011, 43 (12) :1193-1201.

[6]SELMI C, MAYO M J, BACH N, et al.Primary biliary cirrhosis in monozygotic and dizygotic twins:genetics, epigenetics, and environment[J].Gastroenterology, 2004, 127 (2) :485-492.

[7]CAREY EJ, ALI AH, LINDOR KD.Primary biliary cirrhosis[J].Lancet, 2015, 386 (10003) :1565-1576.

[8]HIRSCHFIELD GM, INVERNIZZI P.Progress in the genetics of primary biliary cirrhosis[J].Semin Liver Dis, 2011, 31 (2) :147-156.

[9]HUANG YQ.Recent advances in the diagnosis and treatment of primary biliary cholangitis[J].World J Hepatol, 2016, 8 (33) :1419-1441.

[10]JOSHITA S, UMEMURA T, TANAKA E, et al.Genetic contribution to the pathogenesis of primary biliary cholangitis[J].J Immunol Res, 2017, 2017:3073504.

[11]DONALDSON PT, BARAGIOTTA A, HENEGHAN MA, et al.HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis:a large-scale study[J].Hepatology, 2006, 44 (3) :667-674.

[12]MULLARKEY ME, STEVENS AM, MCDONNELL WM, et al.Human leukocyte antigen class II alleles in Caucasian women with primary biliary cirrhosis[J].Tissue Antigens, 2005, 65 (2) :199-205.

[13]ONISHI S, SAKAMAKI T, MAEDA T, et al.DNA typing of HLAclass II genes;DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis[J].J Hepatol, 1994, 21 (6) :1053-1060.

[14]LIU HY, DENG AM, ZHANG J, et al.Analysis of HLA alleles polymorphism in Chinese patients with primary biliary cirrhosis[J].Chin J Hepatal, 2005, 13 (6) :410-413. (in Chinese) 刘海英, 邓安梅, 张建, 等.原发性胆汁性肝硬化患者人类白细胞抗原等位基因多态性分析[J].中华肝脏病杂志, 2005, 13 (6) :410-413.

[15]JIANG XH, ZHONG RQ, FANG XY, et al.Relationship between alleles of HLA-DRB and HLA-DQB1 and Chinese patients with primary biliary cirrhosis[J].Chin J Hepatol, 2004, 12 (7) :436. (in Chinese) 姜小华, 仲人前, 方晓云, 等.原发性胆汁性肝硬化与HLA-DRB1、DQB1等位基因的相关性研究[J].中华肝脏病杂志, 2004, 12 (7) :436.

[16]LI M, ZHENG H, TIAN QB, et al.HLA-DR polymorphism and primary biliary cirrhosis:evidence from a meta-analysis[J].Arch Med Res, 2014, 45 (3) :270-279.

[17]UMEMURA T, JOSHITA S, ICHIJO T, et al.Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis[J].Hepatology, 2012, 55 (2) :506-511.

[18]KUMAGI T, ABE M, IKEDA Y, et al.Infection as a risk factor in the pathogenesis of primary biliary cirrhosis:pros and cons[J].Dis Markers, 2010, 29 (6) :313-321.

[19]QIU F, TANG R, ZUO X, et al.A genome-wide association study identifies six novel risk loci for primary biliary cholangitis[J].Nat Commun, 2017, 8:14828.

[20]CORDELL HJ, HAN Y, MELLS GF, et al.International genomewide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways[J].Nat Commun, 2015, 6:8019.

[21]NAKAMURA M, NISHIDA N, KAWASHIMA M, et al.Genomewide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population[J].Am J Hum Genet, 2012, 91 (4) :721-728.

[22]LIU JZ, ALMARRI MA, GAFFNEY DJ, et al.Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2012, 44 (10) :1137-1141.

[23]JURAN BD, HIRSCHFIELD GM, INVERNIZZI P, et al.Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants[J].Hum Mol Genet, 2012, 21 (23) :5209-5221.

[24]MELLS GF, FLOYD JA, MORLEY KI, et al.Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis[J].Nat Genet, 2011, 43 (4) :329-332.

[25]LIU X, INVERNIZZI P, LU Y, et al.Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis[J].Nat Genet, 2010, 42 (8) :658-660.

[26]HIRSCHFIELD GM, LIU X, HAN Y, et al.Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis[J].Nat Genet, 2010, 42 (8) :655-657.

[27]HIRSCHFIELD GM, LIU X, XU C, et al.Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants[J].N Engl JMed, 2009, 360 (24) :2544-2555.

[28]van WANROOIJ RL, ZWIERS A, KRAAL G, et al.Genetic variations in interleukin-12 related genes in immune-mediated diseases[J].J Autoimmun, 2012, 39 (4) :359-368.

[29]YANG CY, MA X, TSUNEYAMA K, et al.IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis:implications for therapy[J].Hepatology, 2014, 59 (5) :1944-1953.

[30]HIRSCHFIELD GM, CHAPMAN RW, KARLSEN TH, et al.The genetics of complex cholestatic disorders[J].Gastroenterology, 2013, 144 (7) :1357-1374.

[31]GULAMHUSEIN AF, JURAN BD, LAZARIDIS KN.Genomewide association studies in primary biliary cirrhosis[J].Semin Liver Dis, 2015, 35 (4) :392-401.

[32]PUIMEGE L, LIBERT C, van HAUWERMEIREN F.Regulation and dysregulation of tumor necrosis factor receptor-1[J].Cytokine Growth Factor Rev, 2014, 25 (3) :285-300.

[33]KITAMURA K, NAKAMOTO Y, AKIYAMA M, et al.Pathogenic roles of tumor necrosis factor receptor p55-mediated signals in dimethylnitrosamine-induced murine liver fibrosis[J].Lab Invest, 2002, 82 (5) :571-583.

[34]CHIKUMA S.CTLA-4, an essential immune-checkpoint for T-cell activation[J].Curr Top Microbiol Immunol, 2017.[Epub ahead of print]

[35]WOLF A, BEUERLEIN K, ECKART C, et al.Identification and functional characterization of novel phosphorylation sites in TAK1-binding protein (TAB) 1[J].PLo S One, 2011, 6 (12) :e29256.

[36]ELSHARKAWY AM, OAKLEY F, LIN F, et al.The NF-kappa Bp50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes[J].J Hepatol, 2010, 53 (3) :519-527.

[37]BIANCHI I, CARBONE M, LLEO A, et al.Genetics and epigenetics of primary biliary cirrhosis[J].Semin Liver Dis, 2014, 34 (3) :255-264.

[38]SELMI C, CAVACIOCCHI F, LLEO A, et al.Genome-wide analysis of DNA methylation, copy number variation, and gene expression in monozygotic twins discordant for primary biliary cirrhosis[J].Front Immunol, 2014, 5:128.

[39]HU Z, HUANG Y, LIU Y, et al.beta-Arrestin 1 modulates functions of autoimmune T cells from primary biliary cirrhosis patients[J].J Clin Immunol, 2011, 31 (3) :346-355.

[40]NINOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct microRNAs expression profile in primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers[J].PLo S One, 2013, 8 (6) :e66086.

[41]WEBB GJ, SIMINOVITCH KA, HIRSCHFIELD GM.The immunogenetics of primary biliary cirrhosis:a comprehensive review[J].JAutoimmun, 2015, 64:42-52.

[42]CIRULLI ET, GOLDSTEIN DB.Uncovering the roles of rare variants in common disease through whole-genome sequencing[J].Nat Rev Genet, 2010, 11 (6) :415-425.

[43]SUN L, ZHANG X, HE L.GWAS promotes precision medicine in China[J].J Genet Genomics, 2016, 43 (8) :477-479.

[44]DONG M, LI J, TANG R, et al.Multiple genetic variants associated with primary biliary cirrhosis in a Han Chinese population[J].Clin Rev Allergy Immunol, 2015, 48 (2-3) :316-321.

[45]LAMMERS WJ, HIRSCHFIELD GM, CORPECHOT C, et al.Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy[J].Gastroenterology, 2015, 149 (7) :1804-1812.

[46]SAMUR S, KLEBANOFF M, BANKEN R, et al.Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis[J].Hepatology, 2017, 65 (3) :920-928.

[47]HIRSCHFIELD GM, MASON A, LUKETIC V, et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology, 2015, 148 (4) :751-761.

[48] NEVENS F, ANDREONE P, MAZZELLA G, et al.A placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.

[49]HEGADE VS, KHANNA A, WALKER LJ, et al.Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score[J].Dig Dis Sci, 2016, 61 (10) :3037-3044.

[50]MOUSA H, LLEO A, INVERNIZZI P, et al.Advanced in pharmacotherapy for primary biliary cirrhosis[J].Expert Opin Pharmacother, 2015, 16 (5) :633-643.

[51]EGAWA H, SAKISAKA S, TERAMUKAI S, et al.Long-term outcomes of living-donor liver transplantation for primary biliary cirrhosis:a Japanese multicenter study[J].Am J Transplant, 2016, 16 (4) :1248-1257.

[52]WEBB CF, BRYANT J, POPOWSKI M, et al.The ARID family transcription factor bright is required for both hematopoietic stem cell and B lineage development[J].Mol Cell Biol, 2011, 31 (5) :1041-1053.

[53] MYERS RP, SWAIN MG, LEE SS, et al.B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid[J].Am J Gastroenterol, 2013, 108 (6) :933-941.

[54]DHIRAPONG A, LLEO A, YANG GX, et al.B cell depletion therapy exacerbates murine primary biliary cirrhosis[J].Hepatology, 2011, 53 (2) :527-535.

[55]HIRSCHFIELD GM, GERSHWIN ME, STRAUSS R, et al.Ustekinumab for patients with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid:a proof-of-concept study[J].Hepatology, 2016, 64 (1) :189-199.

[56]TACKE F, LUEDDE T, TRAUTWEIN C.Inflammatory pathways in liver homeostasis and liver injury[J].Clin Rev Allergy Immunol, 2009, 36 (1) :4-12.

[57]XIAO L, JIA L, ZHANG Y, et al.Human IL-21+IFN-gamma+CD4+T cells in nasal polyps are regulated by IL-12[J].Sci Rep, 2015, 5:12781.

[58]MEAGHER C, BEILKE J, ARREAZA G, et al.Neutralization of interleukin-16 protects nonobese diabetic mice from autoimmune type 1 diabetes by a CCL4-dependent mechanism[J].Diabetes, 2010, 59 (11) :2862-2871.

施引文献

资源附件(0)

访问统计